Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. The company operates through Cell Therapy, Degenerative Disease, and BioBanking segments. Its lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. In addition, the company is developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. Celularity Inc. produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is based in Florham Park, New Jersey. more
Time Frame | CELU | Sector | S&P500 |
---|---|---|---|
1-Week Return | -6.09% | 0.49% | -1.93% |
1-Month Return | -7.69% | -3.1% | -3.69% |
3-Month Return | -14.62% | -8.59% | 0.82% |
6-Month Return | -23.4% | -4.57% | 3.51% |
1-Year Return | -13.6% | -0.94% | 21.91% |
3-Year Return | -95.05% | 2.88% | 24.73% |
5-Year Return | -97.83% | 35.84% | 78.4% |
10-Year Return | -97.8% | 98.8% | 187.28% |
Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 14.28M | 21.34M | 17.98M | 22.77M | 22.77M | [{"date":"2020-12-31","value":62.7,"profit":true},{"date":"2021-12-31","value":93.69,"profit":true},{"date":"2022-12-31","value":78.94,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] |
Cost of Revenue | 4.93M | 9.65M | 19.66M | 16.02M | 16.02M | [{"date":"2020-12-31","value":25.08,"profit":true},{"date":"2021-12-31","value":49.09,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":81.44,"profit":true},{"date":"2024-12-31","value":81.44,"profit":true}] |
Gross Profit | 9.35M | 11.68M | (1.69M) | 6.75M | 6.75M | [{"date":"2020-12-31","value":80,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-14.47,"profit":false},{"date":"2023-12-31","value":57.82,"profit":true},{"date":"2024-12-31","value":57.82,"profit":true}] |
Gross Margin | 65.46% | 54.76% | (9.40%) | 29.66% | 29.66% | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":83.65,"profit":true},{"date":"2022-12-31","value":-14.36,"profit":false},{"date":"2023-12-31","value":45.32,"profit":true},{"date":"2024-12-31","value":45.32,"profit":true}] |
Operating Expenses | 87.44M | 159.69M | 146.58M | 99.25M | 199.04M | [{"date":"2020-12-31","value":43.93,"profit":true},{"date":"2021-12-31","value":80.23,"profit":true},{"date":"2022-12-31","value":73.64,"profit":true},{"date":"2023-12-31","value":49.86,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] |
Operating Income | (78.09M) | (148.01M) | (25.60M) | (76.48M) | (192.29M) | [{"date":"2020-12-31","value":-7809100000,"profit":false},{"date":"2021-12-31","value":-14801200000,"profit":false},{"date":"2022-12-31","value":-2560000000,"profit":false},{"date":"2023-12-31","value":-7647900000,"profit":false},{"date":"2024-12-31","value":-19228700000,"profit":false}] |
Total Non-Operating Income/Expense | (62.99M) | 45.08M | 40.17M | (119.81M) | - | [{"date":"2020-12-31","value":-139.75,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":89.12,"profit":true},{"date":"2023-12-31","value":-265.79,"profit":false},{"date":"2024-12-31","value":"-","profit":true}] |
Pre-Tax Income | (212.93M) | (100.10M) | 14.21M | (196.28M) | (196.28M) | [{"date":"2020-12-31","value":-1499,"profit":false},{"date":"2021-12-31","value":-704.67,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-1381.8,"profit":false},{"date":"2024-12-31","value":-1381.8,"profit":false}] |
Income Taxes | (4.70M) | 20.00K | 13.00K | - | 10.00K | [{"date":"2020-12-31","value":-23500,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":65,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":50,"profit":true}] |
Income After Taxes | (208.23M) | (100.12M) | 14.19M | - | - | [{"date":"2020-12-31","value":-1467.26,"profit":false},{"date":"2021-12-31","value":-705.45,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (49.26M) | (100.12M) | 14.19M | (196.29M) | - | [{"date":"2020-12-31","value":-347.1,"profit":false},{"date":"2021-12-31","value":-705.45,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-1383.14,"profit":false},{"date":"2024-12-31","value":"-","profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
Net Income | (208.23M) | (100.12M) | 14.19M | (196.29M) | (196.29M) | [{"date":"2020-12-31","value":-1467.26,"profit":false},{"date":"2021-12-31","value":-705.45,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-1383.14,"profit":false},{"date":"2024-12-31","value":-1383.14,"profit":false}] |
EPS (Diluted) | (0.03) | 0.16 | (0.37) | (1.68) | - | [{"date":"2020-12-31","value":-19.38,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-231.25,"profit":false},{"date":"2023-12-31","value":-1049.06,"profit":false},{"date":"2024-12-31","value":"-","profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
CELU | |
---|---|
Cash Ratio | 0.00 |
Current Ratio | 0.19 |
Quick Ratio | 0.14 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CELU | |
---|---|
ROA (LTM) | -14.63% |
ROE (LTM) | -154.23% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CELU | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.87 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.13 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CELU | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 1.14 |
P/B | 2.81 |
Price/FCF | NM |
EV/R | 2.44 |
EV/Ebitda | NM |
Celularity Inc (CELU) share price today is $2.139
Yes, Indians can buy shares of Celularity Inc (CELU) on Vested. To buy Celularity Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CELU stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Celularity Inc (CELU) via the Vested app. You can start investing in Celularity Inc (CELU) with a minimum investment of $1.
You can invest in shares of Celularity Inc (CELU) via Vested in three simple steps:
The 52-week high price of Celularity Inc (CELU) is $7.97. The 52-week low price of Celularity Inc (CELU) is $1.3.
The price-to-earnings (P/E) ratio of Celularity Inc (CELU) is
The price-to-book (P/B) ratio of Celularity Inc (CELU) is 2.81
The dividend yield of Celularity Inc (CELU) is 0.00%
The market capitalization of Celularity Inc (CELU) is $48.79M
The stock symbol (or ticker) of Celularity Inc is CELU